P-glycoprotein (P-gp) is a major factor in the multidrug resistance phenotype in cancer cells.
P-gp is a protein that regulates the ATP-dependent efflux of a wide range of anticancer …

Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease with a chronic,
progressive course. Various aspects of PsA, including its clinical features, disease course …

Suppressing inflammation has been the primary focus of therapies in autoimmune rheumatic
diseases (AIRDs), including rheumatoid arthritis and systemic lupus erythematosus …

Through treatment with biological DMARDs (bDMARDs) or targeted synthetic (tsDMARDs)
such as Janus kinase (JAK) inhibitors in addition to MTX, clinical remission has become a …

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …

Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …

Introduction Treatment with biologics often leads to clearance of psoriasis. However, some
patients do repeatedly fail to respond and/or lose an achieved response (treatment …

Engineered microbes for the delivery of biologics are a promising avenue for the treatment
of various conditions such as chronic inflammatory disorders and metabolic disease. In this …

ABSTRACT Introduction As of May 2023, 19 and 18 biosimilars have been approved for the
treatment of rheumatoid arthritis (RA) by the European Medicines Agency (EMA) and United …

In recent years, difficult-to-treat rheumatoid arthritis (D2T RA) has attracted significant
attention from rheumatologists due to its poor treatment response and the persistent …